Macro Group registers 21.2% YoY consolidated profit hike in 9 months
Updated 11/3/2022 11:33:00 AM
Arab Finance: Macro Group Pharmaceutical (Macro Capital) (MCRO) posted a 21.21% year-on-year (YoY) increase in consolidated profit attributable to the parent company during the first nine months of 2022, according to financial statements filed to the Egyptian Exchange (EGX) on November 3rd.
The company’s consolidated profit excluding minority interest rose to EGP 129.449 million in the nine-month period ended September 30th from EGP 106.796 million in the same period a year earlier.
Net sales jumped to EGP 520.301 million in the January-September period of 2022 from EGP 417.143 million in the year-ago period.
Furthermore, the standalone net profit after tax grew to EGP 128.767 million during the period from January 1st to September 30th from EGP 106.138 million in the same period last year.
Founded in 2002, Macro Group is a leading Egyptian cosmeceutical company based in Cairo.
